TriangleHEALTH PROFESSIONAL · SOURCE READING
Everolimus
Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: October 25, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Evidence (everolimus):
A phase II study included 51 patients with recurrent TETs (32 with thymoma and 19 with thymic carcinoma). Patients received oral everolimus at a dose of 10 mg per day.[7][Level of evidence C3]
Source links and citations
A phase II study included 51 patients with recurrent TETs (32 with thymoma and 19 with thymic carcinoma). Patients received oral everolimus at a dose of 10 mg per day.[7][Level of evidence C3]
Objective responses were observed in 3 of 32 patients (9.4%) with thymoma and in 3 of 19 patients (15.8%) with thymic carcinoma.
A phase II study included 51 patients with recurrent TETs (32 with thymoma and 19 with thymic carcinoma). Patients received oral everolimus at a dose of 10 mg per day.[7][Level of evidence C3]
The disease-control rate was 88% (thymoma: 93.8%; thymic carcinoma: 77.8%).
A phase II study included 51 patients with recurrent TETs (32 with thymoma and 19 with thymic carcinoma). Patients received oral everolimus at a dose of 10 mg per day.[7][Level of evidence C3]
After a median follow-up of 25.7 months, the median PFS was 10.1 months (thymoma: 16.6 months; thymic carcinoma: 5.6 months).
A phase II study included 51 patients with recurrent TETs (32 with thymoma and 19 with thymic carcinoma). Patients received oral everolimus at a dose of 10 mg per day.[7][Level of evidence C3]
The median OS was 25.7 months (thymoma: not reached; thymic carcinoma: 14.7 months).
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice